The Journal of ECT

Skip Navigation LinksHome > December 2011 - Volume 27 - Issue 4 > Iodine-123 Fluoropropyl-Carbomethoxy-3-β-(4-Iodophenyltropan...
Journal of ECT:
doi: 10.1097/YCT.0b013e31821646b6
Case Reports

Iodine-123 Fluoropropyl-Carbomethoxy-3-β-(4-Iodophenyltropane) Single-Photon Emission Computed Tomography Findings Before and After Electroconvulsive Therapy in Major Depressive Disorder With Parkinsonism

Bui, Eric MD, PhD*; Delrieu, Julien MD; Wagner, Thomas MD; Rieu, Julie MD*; Véry, Etienne MD*; Letamendia, Clara MD*; Payoux, Pierre MD, PhD; Schmitt, Laurent MD*

Collapse Box


Background: To date, only a few cases of improvement of Parkinsonism in depressed patients treated with electroconvulsive therapy (ECT) have been reported. However, no functional imaging data are available to support this finding.

Objective: To describe the first observation of increase in dopamine transporter uptake after ECT.

Methods: Iodine-123 fluoropropyl-carbomethoxy-3-β-(4-iodophenyltropane) single-photon emission computed tomographic imaging was conducted in a 77-year-old depressed patient displaying symptoms of Parkinson disease (PD) before and after a series of 12 bilateral ECTs.

Results: The patient displayed improvement in PD symptoms and increase in dopamine transporter uptake after ECT.

Conclusions: Our observation suggests that the PD symptoms and decrease in striatal uptake appearing in the context of a depressive episode might warrant further attention, as they might be reversible.

© 2011 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.